INNOVATION

This Tactical Proposal, funded in 2023 by the Prostate Cancer Foundation, represents a first-in-field comprehensive effort to address the heath burden resulting from tumor heterogeneity by acquiring a detailed, quantitative and multidimensional view of tumor and host components. These data will drive a detailed understanding of metastatic castration-resistant prostate cancer (mCRPC) that will be exploited through the development of new therapeutic trials.

We believe that the work of our researchers and clinicians will help advance our understanding of tumor and host heterogeneity in mCRPC, providing a foundation for the development of therapeutic approaches directed against this heterogeneity.